SCHEMBL2726673

SCHEMBL2726673

Cc1csc([C@H]2CCCN2C(=O)c2ccnc(-c3nnc([C@@](C)(Cc4ccccc4)NC(=O)O)o3)c2)n1

nearest known ligand 0.39

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.38
TRPV1 Q8NER1 2/20 0.37
CPT1A P50416 8/20 0.36
CPT2 P23786 7/20 0.36
PKM P14618 1/20 0.35
POLB P06746 1/20 0.35
AADAT Q8N5Z0 1/20 0.34
NAA50 Q9GZZ1 1/20 0.34
SCN9A Q15858 1/20 0.34
CPT1B Q92523 2/20 0.34
SCD5 Q86SK9 1/20 0.34
MAP3K12 Q12852 1/20 0.34
HCRTR1 O43613 1/20 0.33
HCRTR2 O43614 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2728954 0.94 ACACB (0.38) SMN1; SMN2TRPV1CPT1ACPT2PKM
SCHEMBL2728191 0.92 SMN1; SMN2 (0.38) SMN1; SMN2TRPV1CPT1ACPT2PKM
SCHEMBL10290682 0.91 CPT1A (0.37) SMN1; SMN2TRPV1CPT1ACPT2PKM
SCHEMBL2710979 0.91 CPT1A (0.37) SMN1; SMN2TRPV1CPT1ACPT2PKM
SCHEMBL2727845 0.90 CPT1A (0.39) SMN1; SMN2TRPV1CPT1ACPT2POLB
SCHEMBL2727033 0.90 SMN1; SMN2 (0.37) SMN1; SMN2TRPV1CPT1ACPT2PKM
SCHEMBL2726866 0.90 SMN1; SMN2 (0.37) SMN1; SMN2TRPV1CPT1ACPT2PKM
SCHEMBL2728180 0.89 HCRTR1 (0.38) SMN1; SMN2TRPV1POLBHCRTR1HCRTR2
SCHEMBL2724978 0.89 SMN1; SMN2 (0.37) SMN1; SMN2TRPV1CPT1ACPT2POLB
SCHEMBL2727131 0.89 SMN1; SMN2 (0.38) SMN1; SMN2TRPV1CPT1ACPT2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012054510-A1 OXADIAZOLE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF COMENTIS, INC. (US) 2012-04-26 WO disclosed